|
 |
|
|
|
|
| Carcinoembryonic antigen-related cell adhesion molecules (CEACAMs) 是CEA家族中之一的重要亞族。人類擁有12種，分別是CEACAM1 ,CEACAM3, 4, 5, 6, 7, 8, CEACAM16和CEACAM18, 19, 20和 CEACAM21. 實驗中發現CEACAM1、CEACAM5和CEACAM6，在幾種實體腫瘤中過度表達，成為腫瘤免疫治療的有希望的靶點，推動 bispecific antibodies (BsAbs), bispecific T cell engagers (BiTE), chimeric antigen receptor T cells (CAR-T) 和 antibody-drug conjugates (ADCs). 等先進技術的發展。截至2023年11月，tusamitamab ravtansine為正在臨床試驗中評估的一種ADC，專門針對非小細胞肺癌(NSCLC)患者中的CEACAM5。Sino Biological認可CEACAMs的重要性，提供一系列經純度(SEC-HPLC)和生物活性驗證的重組CEACAM蛋白。相對應的CEACAM抗體也經過嚴格的驗證以應用於特定實驗。
|
|
|
|
|
|
|
特色CEACAM重組蛋白產品
|
|
|
|
|
Human CEACAM-1/CD66a Protein
|
Human CEACAM-6/CD66c Protein
|
|
HPLC-verified Cat#: 10822-H08H
|
HPLC-verified Cat#: 10823-H08H
|
|
|
|
|
Activity-validated:
Ability to inhibit IL2 secretion by HuT 78 human cutaneous T cell lymphoma cells.
|
Activity-validated:
Immobilized human CEACAM6-his can bind human CEACAM8-his.
|
|
|
|
Human CEACAM-5/CD66e Protein
|
Human CEACAM-8/CD66b Protein
|
|
HPLC-verified Cat#: 11077-H41H-B
|
HPLC-verified Cat#: 11729-H08H
|
|
|
|
|
Purity:
≥ 95 % as determined by SEC-HPLC.
|
Purity:
≥ 90 % as determined by SEC-HPLC.
|
|
|
|
|
|
|
特色CEACAM抗體產品
|
|
|
|
Anti-CEACAM-5/CD66e Antibody
Rabbit mAb
|
Anti-CEACAM-6/CD66c Antibody
Rabbit mAb
|
|
3 Citations Cat#: 11077-R327
Applications: IHC-P
|
2 Citations Cat#: 10823-R408
Applications: ELISA, FCM, ICC/IF
|
|
|
|
|
Immunochemical staining of human CEACAM5 in human colon carcinoma.
|
Immunofluorescence staining of Human CEACAM6 in SKBR3 cells.
|
|
|
|
|
更多CEACAM抗體資訊
|
|
|
|
|
|
|
|
